Brief Title
A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
Official Title
A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B
Brief Summary
This study will examine the long-term safety and efficacy of rIX-FP for the control and
prevention of bleeding episodes in children and adults with severe hemophilia B. The study
will include subjects who have not previously been treated with Factor IX products, subjects
who previously completed a CSL-sponsored rIX-FP lead-in study and subjects requiring major
non-emergency surgery who have not previously completed a CSL-sponsored rIX-FP lead-in study.
A surgical prophylaxis substudy will examine the efficacy of rIX-FP in subjects with
hemophilia B who are undergoing non-emergency major or minor surgery. An additional substudy
will examine the safety and PK of subcutaneous (SC) administration of rIX-FP.
Study Phase
Phase 3
Study Type
Interventional
Primary Outcome
Total number of subjects who develop inhibitors against factor IX (FIX)
Secondary Outcome
Comparison of annualized bleeding rate between different prophylaxis treatment intervals.
Condition
Hemophilia B
Intervention
rIX-FP
Study Arms / Comparison Groups
rIX-FP
Description: Subjects will administer rIX-FP by intravenous infusion as routine prophylaxis, prevention, and on-demand treatment during a treatment period of approximately 3 years. The routine prophylaxis treatment interval for previously treated patients may be changed at each scheduled 6-month follow-up assessment. On-demand treatment with rIX-FP will be used for all bleeding episodes requiring treatment. Subjects (other than those in France) may participate in a surgical 'substudy' in which rIX-FP may be administered before, during and after surgery. An additional substudy will examine the safety and PK of subcutaneous administration of rIX-FP. For previously untreated patients, subjects will administer rIX-FP intravenously as weekly prophylaxis and/or on-demand treatment during the first 12 months, and as weekly routine prophylaxis thereafter. The dose of rIX-FP administered will be based on the subject's previous rIX-FP use and/or pharmacokinetic data.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Biological
Estimated Enrollment
97
Start Date
February 6, 2014
Completion Date
June 2, 2021
Primary Completion Date
June 2, 2021
Eligibility Criteria
Inclusion criteria:
Main study inclusion criteria:
For previously treated subjects, either:
- Completed a CSL-sponsored rIX-FP (CSL654) study, including study CSL654_3001
[NCT01496274] or study CSL654_3002 [NCT01662531].
Or:
- Scheduled to have a major non-emergency surgery within approximately 8 weeks from the
anticipated date of receiving the first rIX-FP injection.
- Not previously completed a CSL-sponsored rIX-FP lead-in study.
- Male, 12 to 70 years of age.
- Documented severe hemophilia B (FIX activity of ≤ 2%), or confirmed at screening by
the central laboratory.
- Subjects who have received FIX products (plasma-derived and / or recombinant FIX) for
> 150 exposure days (EDs), confirmed by their treating physician.
- No confirmed history of FIX inhibitor formation at screening by the central laboratory
For previously untreated subjects:
- Male, up to 18 years of age.
- Documented severe hemophilia B (FIX activity of ≤ 2%), or confirmed at screening by
the central laboratory.
- Never previously been treated with FIX clotting factor products (except previous
exposure to blood components).
- No confirmed history of FIX inhibitor formation
Surgery substudy inclusion criterion:
- Must require non-emergency surgery
Subcutaneous substudy inclusion criteria:
- Male, at least 18 years of age.
- Subjects currently enrolled in Study CSL654_3003
- Subjects who have received rIX-FP for ≥ 100 EDs (single-dose cohorts) or for ≥ 50 EDs
(repeated-dose cohort)
Exclusion criteria:
Main study exclusion criteria:
- Currently receiving a therapy not permitted during the study.
- Any issue that, in the opinion of the investigator, would render the subject
unsuitable for participation in the study.
For subjects who have previously completed a CSL-sponsored rIX-FP study:
- Unwilling to participate in the study for a total of 100 exposure days.
For subjects requiring major non-emergency surgery who have not previously completed a
CSL-sponsored rIX-FP lead-in study:
- Known hypersensitivity (ie, allergic reaction or anaphylaxis) to any FIX product or
hamster protein.
- Known congenital or acquired coagulation disorder other than congenital FIX
deficiency.
- Currently receiving IV immunomodulating agents such as immunoglobulin or chronic
systemic corticosteroid treatment.
- Low platelet count, kidney or liver disease.
- Human immunodeficiency virus positive with a CD4 count < 200/mm3.
For previously untreated subjects:
- Known congenital or acquired coagulation disorder other than congenital FIX deficiency
(except for vitamin K deficiency of the newborn).
- Known kidney or liver dysfunction or any condition which, in the investigator's
opinion, place the patient at unjustifiable risk.
The surgical substudy does not have any additional exclusion criteria, although subject(s)
in France will not be eligible for the surgery sub-study.
Subcutaneous substudy exclusion criteria:
- Intravenous use of rIX-FP within 14 days of subcutaneous administration of rIX-FP.
- Life-threatening bleeding episode or major surgery during the 3 months prior to
substudy entry
Gender
Male
Ages
N/A - 70 Years
Accepts Healthy Volunteers
No
Contacts
Program Director, ,
Location Countries
Australia
Location Countries
Australia
Administrative Informations
NCT ID
NCT02053792
Organization ID
CSL654_3003
Secondary IDs
2012-005489-37
Responsible Party
Sponsor
Study Sponsor
CSL Behring
Study Sponsor
Program Director, Study Director, CSL Behring
Verification Date
November 2021